Early Warning -
Early Action

IscAlert™ is a miniaturized disposable
biosensor that provides early
warning of ischemia.

A lifesaver Biomarker

Carbon dioxide (CO2) is an end-metabolic product of all cells in all tissues. The human body keeps the tissue levels of CO2 in a narrow and very well controlled range. Any change of the tissue CO2 (or) level is considered pathologic, indicating either insufficient blood or oxygen to the tissue (ischemia), or excess oxygen to the tissue (hyperventilation).

The Unique Sensor Technology

SensoCure is the owner of a unique proprietary technology for detecting the tissue pCO2 level. The tissue pCO2 level may change due to critical perfusion, respiration or metabolic conditions. The SensoCure pCO2 technology gives basis for a row of products for early detection of either critical local or systemic conditions with high mortality and considerable cost to the health care providers.

The Product

IscAlert ™ offers a numbers of benefits


IscAlert™ addresses a largely unmet medical need as a user friendly, fast, robust real time monitoring device of ischemia.


IscAlert™ fits well into current medical practice by giving improved patient outcome and therefore substantially reduces healthcare costs by lowering the need for e.g. intensive care.


IscAlert™ is a direct and realtime method for measuring Ischemia.

Sensocure AS

Sensocure AS develops biomedical
sensors for healthcare. The main product
under development is IscAlert™, a CO2
sensor designed for the earliest possible
detection of ischemia.

Press and public relations

Sensocure one of Financial Times 1000 fastest growing companies

We are proud to announce that Sensocure has earned position no. 482 in the 5th annual edition of the FT1000 Europe’s Fastest Growing Companies ranking.  The rating is the result of a joint initiative by the Financial Times and Statista, which conducted months of...

NFR støtter vårt CANARY prosjekt

Gjennom «Innovasjonsprosjekt i næringslivet», finansierer Norges Forskningsråd prosjekter med omfattende innhold av forsknings- og utviklingsaktiviteter, som skal gi et betydelig bidrag til fornyelse og økt verdiskaping for bedriftene som deltar i prosjektet, og for...

Funding from Innovation Norway

We have received funding from Innovation Norway for optimalization of our calibration method. In this project we will develop a one-stop-calibration method which is fast, robust and user friendly. The project period for project KALISC II will be from 2020-2023.